The Whole World Is Celebrating This News: Diabetes Vaccine Officially Revealed !
There are 1,25 million people in America alone suffering from type 1 diabetes. Bacillus Calmette-Guerin is a vaccine that has been used for tuberculosis 100 years ago and this vaccine seems to be the solution for this problem. Nowadays, this vaccine is used as a treatment for bladder cancer. To add, this vaccine is believed that it is safe.
There was an announcement yesterday during the 75th Scientific Sessions of the American Diabetes Association which said 150 people with advanced type 1 diabetes are going to receive this vaccine as part of a test.
In case of type 1 diabetes, the body doesn’t produce insulin because the cells that create insulin are killed by the immune system. However, T cells are created and they lead to issues in the pancreatic islets. Insulin is produced here. This vaccine eliminates T cells.
Patients with diabetes injected with the vaccine saw an increase in the levels of a substance called tumor necrosis factor. The increased level of TNF in the system destroys the T cells that are hindering the production of insulin.
In a previous trial, patients were injected with the tuberculosis vaccine twice within a four-week time frame. The results showed that the dangerous T cells were gone, and some people even began to secrete insulin on their own.
Dr. Denise Faustman, director of the Massachusetts General Hospital Immunobiology Laboratory in Boston, is very excited about the results the BCG vaccine has been showing.
“In the phase I (preliminary) trial we demonstrated a statistically significant response to BCG, but our goal in (this trial) is to create a lasting therapeutic response. We will be working again with people who have had type 1 diabetes for many years. This is not a prevention trial; instead, we are trying to create a regimen that will treat even advanced disease.”
This new five-year trial will start this summer. Those who are enrolled will range in ages from 18 to 60-years-old. The trial will use the same format as was used before by injecting patients twice within a four-week period. Patients will then have one injection a year for the next four years.
Not all diabetes experts are confident that this treatment will work. Robert Sobel, an assistant professor of endocrinology at Northwestern University’s Feinberg School of Medicine, explains why he is skeptical.
“I think it’s a stretch to say this would have a huge impact on the millions plus type I diabetes patients in this country. We would love to do something to preserve or repopulate their beta cell mass. Historically, we have watched it dwindle and have not been able to do something (in time).”
Time will tell if this vaccine will become a viable treatment option for type 1 diabetes or not.